My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.
As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.
Anke van den Berg
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
I have a central role in all research projects focusing on the role of noncoding RNAs. My main aim is to understanding how small and long non-coding RNAs contribute to the pathogenesis of B-cell lymphoma. Ongoing studies include MYC-regulated miRNAs and lncRNAs, as well as miRNA-lncRNA interactions and the role of circular RNAs. We apply state-of-the-art methodology including AGO2-RIP, RNA-FISH and gain- and loss-of-function screens using shRNA and CRISPR-Cas technology.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Tom van Meerten
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists.
Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
In my profession as a nuclear medicine physician, I’m involved in both clinical and scientific applications of nuclear medicine and radiology modalities. My main interests include haematology, general oncology, radio-immunotherapy, and especially the implementation of new therapeutic strategies. Currently, I have a special interest in imaging post-transplant lymphoproliferative disease, as well as radio-immunotherapy in chemotherapy refractory (non)-Hodgkin’s lymphoma.